Kura Oncology stock: valuation and P/E
KURAHere you can see what Kura Oncology, Inc. costs today relative to earnings, sales and book value, and how that compares with its own valuation history. A high P/E is not a verdict by itself; what matters is whether it sits above or below what the market usually grants this company.
Daily figure as of 13 Nov 2026
P/E on expected earnings
The 10 analysts expect a loss of $2.53 per share on average for the next twelve months, so there is no forward P/E.
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
There is no reliable data on this for this company.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.